Caballero-Villarraso J - Search Results

1

Neuroprotective and antioxidant effects of docosahexaenoic acid (DHA) in an experimental model of multiple sclerosis.

Muñoz-Jurado A, Escribano BM, Galván A, Valdelvira ME, Caballero-Villarraso J, Giraldo AI, Santamaría A, Luque E, Agüera E, LaTorre M, Túnez I. Muñoz-Jurado A, et al. Among authors: caballero villarraso j. J Nutr Biochem. 2024 Feb;124:109497. doi: 10.1016/j.jnutbio.2023.109497. Epub 2023 Oct 23. J Nutr Biochem. 2024. PMID: 37875228

2

Interrelationships Among Gut Microbiota and Host: Paradigms, Role in Neurodegenerative Diseases and Future Prospects.

Caballero-Villarraso J, Galvan A, Escribano BM, Tunez I. Caballero-Villarraso J, et al. CNS Neurol Disord Drug Targets. 2017;16(8):945-964. doi: 10.2174/1871527316666170714120118. CNS Neurol Disord Drug Targets. 2017. PMID: 28714393 Review.

3

Dose-dependent S-allyl cysteine ameliorates multiple sclerosis disease-related pathology by reducing oxidative stress and biomarkers of dysbiosis in experimental autoimmune encephalomyelitis.

Escribano BM, Luque E, Aguilar-Luque M, Feijóo M, Caballero-Villarraso J, Torres LA, Ramirez V, García-Maceira FI, Agüera E, Santamaria A, Túnez I. Escribano BM, et al. Eur J Pharmacol. 2017 Nov 15;815:266-273. doi: 10.1016/j.ejphar.2017.09.025. Epub 2017 Sep 19. Eur J Pharmacol. 2017. PMID: 28939293

4

Comparative of transcranial magnetic stimulation and other treatments in experimental autoimmune encephalomyelitis.

Medina-Fernandez FJ, Escribano BM, Luque E, Caballero-Villarraso J, Gomez-Chaparro JL, Feijoo M, Garcia-Maceira FI, Pascual-Leone A, Drucker-Colin R, Tunez I. Medina-Fernandez FJ, et al. Brain Res Bull. 2018 Mar;137:140-145. doi: 10.1016/j.brainresbull.2017.11.018. Epub 2017 Dec 1. Brain Res Bull. 2018. PMID: 29198860

5

Implications of Vitamin D in Multiple Sclerosis and Other Neurodegenerative Processes: Bibliometric Analysis and Systematic Review.

Caballero-Villarraso J, Jiménez-Jiménez MJ, Escribano BM, Agüera E, Santamaría A, Túnez I. Caballero-Villarraso J, et al. CNS Neurol Disord Drug Targets. 2019;18(6):478-490. doi: 10.2174/1871527318666190703102330. CNS Neurol Disord Drug Targets. 2019. PMID: 31269889

6

Extra-Virgin Olive Oil Modifies the Changes Induced in Non-Nervous Organs and Tissues by Experimental Autoimmune Encephalomyelitis Models.

Conde C, Escribano BM, Luque E, Feijóo M, Caballero-Villarraso J, Valdelvira ME, Ochoa-Sepúlveda JJ, Lillo R, Paz E, Santamaría A, Agüera E, Túnez I. Conde C, et al. Nutrients. 2019 Oct 14;11(10):2448. doi: 10.3390/nu11102448. Nutrients. 2019. PMID: 31615022 Free PMC article.

7

Clinical and Neurochemical Effects of Transcranial Magnetic Stimulation (TMS) in Multiple Sclerosis: A Study Protocol for a Randomized Clinical Trial.

Agüera E, Caballero-Villarraso J, Feijóo M, Escribano BM, Conde C, Bahamonde MC, Giraldo AI, Paz-Rojas E, Túnez I. Agüera E, et al. Front Neurol. 2020 Aug 11;11:750. doi: 10.3389/fneur.2020.00750. eCollection 2020. Front Neurol. 2020. PMID: 32849212 Free PMC article.

8

Impact of Repetitive Transcranial Magnetic Stimulation on Neurocognition and Oxidative Stress in Relapsing-Remitting Multiple Sclerosis: A Case Report.

Agüera E, Caballero-Villarraso J, Feijóo M, Escribano BM, Bahamonde MC, Conde C, Galván A, Túnez I. Agüera E, et al. Front Neurol. 2020 Aug 7;11:817. doi: 10.3389/fneur.2020.00817. eCollection 2020. Front Neurol. 2020. PMID: 32903741 Free PMC article.

9

Gene and cell therapy and nanomedicine for the treatment of multiple sclerosis: bibliometric analysis and systematic review of clinical outcomes.

Caballero-Villarraso J, Sawas J, Escribano BM, Martín-Hersog FA, Valverde-Martínez A, Túnez I. Caballero-Villarraso J, et al. Expert Rev Neurother. 2021 Apr;21(4):431-441. doi: 10.1080/14737175.2021.1886926. Epub 2021 Feb 22. Expert Rev Neurother. 2021. PMID: 33554666

10

Mechanisms Involved in Neuroprotective Effects of Transcranial Magnetic Stimulation.

Caballero-Villarraso J, Medina FJ, Escribano BM, Agüera E, Santamaría A, Pascual-Leone A, Túnez I. Caballero-Villarraso J, et al. CNS Neurol Disord Drug Targets. 2022;21(7):557-573. doi: 10.2174/1871527320666210809121922. CNS Neurol Disord Drug Targets. 2022. PMID: 34370648

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

61 results

Search Page